VIRTUAL Off-the-Shelf Allogeneic EBV T Cells: Ushering in the Next Wave of Innovation

Time: 3:00 pm
day: Bootcamp Day


  • Discuss the journey that led to the historic EU approval of the first-ever allogeneic T-cell therapy globally 
  • Highlight the qualities that make allogeneic Epstein-Barr virus (EBV) T cells a highly versatile platform for targeting EBV-driven disease 
  • Explore how this platform can be modified with a chimeric antigen receptor (CAR) to target a wide range of non-EBV-associated disease